Bleakley Financial Group LLC Has $222,000 Stock Holdings in STERIS plc (NYSE:STE)

Bleakley Financial Group LLC reduced its position in shares of STERIS plc (NYSE:STE) by 35.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,078 shares of the medical equipment provider’s stock after selling 602 shares during the quarter. Bleakley Financial Group LLC’s holdings in STERIS were worth $222,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of STE. Magnolia Capital Advisors LLC grew its position in shares of STERIS by 1.9% in the fourth quarter. Magnolia Capital Advisors LLC now owns 2,534 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 48 shares during the last quarter. SkyView Investment Advisors LLC boosted its position in shares of STERIS by 1.6% in the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after acquiring an additional 51 shares during the period. Park Edge Advisors LLC grew its stake in shares of STERIS by 1.1% in the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock worth $958,000 after acquiring an additional 51 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 76 shares during the last quarter. Finally, Metis Global Partners LLC grew its position in STERIS by 1.6% in the 3rd quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock worth $1,322,000 after purchasing an additional 84 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Down 2.0 %

NYSE:STE opened at $219.00 on Thursday. The company has a current ratio of 2.13, a quick ratio of 1.55 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $21.62 billion, a price-to-earnings ratio of 46.50 and a beta of 0.84. The business’s 50-day moving average price is $212.81 and its two-hundred day moving average price is $224.37. STERIS plc has a 1-year low of $197.82 and a 1-year high of $248.24.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, equities analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.04%. STERIS’s dividend payout ratio is currently 48.41%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on STE shares. JMP Securities restated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Thursday, February 6th. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Finally, Stephens reaffirmed an “overweight” rating and set a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $258.75.

Insiders Place Their Bets

In other news, SVP Cary L. Majors sold 1,682 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.